Beibei Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Beibei Guo has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Feng Yang
School of Pharmacy, Naval Medical University, Shanghai 200433, China
3 shared publications Jiao Zhou
Department of Inorganic Chemistry, School of Pharmacy, Naval Medical University, 325 Guohe Road, Shanghai, 200433, China
3 shared publicationsSizhen Wang
Department of Inorganic Chemistry, School of Pharmacy, Naval Medical University, 325 Guohe Road, Shanghai, 200433, China
3 shared publicationsZhendong Chen
Department of Inorganic Chemistry, School of Pharmacy, Naval Medical University, 325 Guohe Road, Shanghai, 200433, China
3 shared publicationsLinhong Sun
Department of Inorganic Chemistry, School of Pharmacy, Naval Medical University, 325 Guohe Road, Shanghai, 200433, China
2 shared publicationsWeiwei Jiang
School of Pharmacy, Naval Medical University
2 shared publications
Latest Publications
- Open Access
- 21 June 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (6) , 760
Engineered Lipid Nanoparticles with Promoted Endosomal Escape and R283S-Mediated Stimulator of Interferon Genes (STING) Activation for Pancreatic Cancer Immunotherapy
Background/Objectives: Lipid nanoparticles (LNPs) have emerged as crucial vehicles for messenger RNA (mRNA) applications in antitumor therapy. Combining LNPs with stimulator of interferon genes (STING) activation holds promise for treating “cold” tumors such as pancreatic cancer. However, two major challenges remain: inefficient mRNA escape from endosomes and STING pathway suppression in immunosuppressive tumor microenvironments. Methods: To improve endosomal escape, we developed a novel pH-responsive PEGylated lipid (Ben-mPEG2000) for mRNA-LNP preparation while using commercial Man-mPEG2000 for dendritic cell (DC)-targeted delivery of LNPs; to alleviate suppression of the STING pathway in the tumor microenvironment and activate immune responses, STING-R283S mRNA was encapsulated into LNPs, ultimately resulting in DC-targeted/pH-responsive LNPs loaded with STING-R283S mRNA for pancreatic cancer immunotherapy research. Results: After pH-responsive cleavage, Ben-mPEG2000 not only enhanced the positive charge of LNPs through the exposed protonated amino groups but also eliminated the PEG-induced steric hindrance effect. The combination of these two effects promoted membrane fusion between LNPs and the endosome, thereby enhancing mRNA translation. As a payload, STING-R283S could further amplify STING signaling in DCs without cytotoxicity to counteract immunosuppression in pancreatic cancer. Conclusions: This engineered LNP platform enhanced mRNA expression and STING activation in DCs, improving immunotherapy outcomes in pancreatic cancer.
- 21 June 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (6) , 760
Open AccessEngineered Lipid Nanoparticles with Promoted Endosomal Escape and R283S-Mediated Stimulator of Interferon Genes (STING) Activation for Pancreatic Cancer Immunotherapy
Background/Objectives: Lipid nanoparticles (LNPs) have emerged as crucial vehicles for messenger RNA (mRNA) applications in antitumor therapy. Combining LNPs with stimulator of interferon genes (STING) activation holds promise for treating “cold” tumors such as pancreatic cancer. However, two major challenges remain: inefficient mRNA escape from endosomes and STING pathway suppression in immunosuppressive tumor microenvironments. Methods: To improve endosomal escape, we developed a novel pH-responsive PEGylated lipid (Ben-mPEG2000) for mRNA-LNP preparation while using commercial Man-mPEG2000 for dendritic cell (DC)-targeted delivery of LNPs; to alleviate suppression of the STING pathway in the tumor microenvironment and activate immune responses, STING-R283S mRNA was encapsulated into LNPs, ultimately resulting in DC-targeted/pH-responsive LNPs loaded with STING-R283S mRNA for pancreatic cancer immunotherapy research. Results: After pH-responsive cleavage, Ben-mPEG2000 not only enhanced the positive charge of LNPs through the exposed protonated amino groups but also eliminated the PEG-induced steric hindrance effect. The combination of these two effects promoted membrane fusion between LNPs and the endosome, thereby enhancing mRNA translation. As a payload, STING-R283S could further amplify STING signaling in DCs without cytotoxicity to counteract immunosuppression in pancreatic cancer. Conclusions: This engineered LNP platform enhanced mRNA expression and STING activation in DCs, improving immunotherapy outcomes in pancreatic cancer.
- Open Access
- 10 June 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Dual-responsive polypyridyl Ru(II)-scaffolded hydrogel for trinitarian tumor therapy activated by mono-wavelength photo-irradiation
Metal-coordinated hydrogels offer a strategy to integrate local drug retention, responsive release, and multimodal therapy, but assigning structural and therapeutic roles to a single metal complex remains challenging. Here, we report an injectable polypyridyl Ru(II)-scaffolded hydrogel, Ru(fmb)3HADH-PDA@IR780, formed by dynamic Schiff-base crosslinking and loaded with polydopamine nanoparticles carrying IR780. In this platform, PDA@IR780 enables 808 nm near-infrared-activated photothermal and photodynamic outputs whereas the Ru(II) complex functions as both a hydrogel crosslinking unit and a redox-active therapeutic component. This formulation demonstrates dual pH/photo-responsiveness: acidic tumor microenvironment (TME) promoted formulation release, and NIR irradiation triggered rapid local heating and reactive oxygen species (ROS) generation. In vitro, the hydrogel produced enhanced tumor-cell killing through combined photothermal, photodynamic, and Ru-associated oxidative and chemodynamic therapy (CDT), accompanied by glutathione depletion and lipid-peroxidation-related stress. In vivo, local administration followed by short NIR irradiation markedly suppressed tumor growth, increased tumor-cell apoptosis, prolonged tumor-site retention, and showed no obvious short-term systemic toxicity under the tested regimen. Transcriptomic and histological analyses further suggested treatment-associated redox disruption and favorable modulation of the local immune microenvironment. This Ru(II)-scaffolded hydrogel provides a component-defined, single-wavelength-activated platform for locally retained multimodal tumor therapy. Notably, this work represents the first report of a polypyridyl Ru(II)-scaffolded hydrogel that unifies Ru(II)'s structural coordination with intrinsic therapeutic action, offering a translational strategy for synergistic, site-selective tumor therapy.
- 10 June 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessDual-responsive polypyridyl Ru(II)-scaffolded hydrogel for trinitarian tumor therapy activated by mono-wavelength photo-irradiation
Metal-coordinated hydrogels offer a strategy to integrate local drug retention, responsive release, and multimodal therapy, but assigning structural and therapeutic roles to a single metal complex remains challenging. Here, we report an injectable polypyridyl Ru(II)-scaffolded hydrogel, Ru(fmb)3HADH-PDA@IR780, formed by dynamic Schiff-base crosslinking and loaded with polydopamine nanoparticles carrying IR780. In this platform, PDA@IR780 enables 808 nm near-infrared-activated photothermal and photodynamic outputs whereas the Ru(II) complex functions as both a hydrogel crosslinking unit and a redox-active therapeutic component. This formulation demonstrates dual pH/photo-responsiveness: acidic tumor microenvironment (TME) promoted formulation release, and NIR irradiation triggered rapid local heating and reactive oxygen species (ROS) generation. In vitro, the hydrogel produced enhanced tumor-cell killing through combined photothermal, photodynamic, and Ru-associated oxidative and chemodynamic therapy (CDT), accompanied by glutathione depletion and lipid-peroxidation-related stress. In vivo, local administration followed by short NIR irradiation markedly suppressed tumor growth, increased tumor-cell apoptosis, prolonged tumor-site retention, and showed no obvious short-term systemic toxicity under the tested regimen. Transcriptomic and histological analyses further suggested treatment-associated redox disruption and favorable modulation of the local immune microenvironment. This Ru(II)-scaffolded hydrogel provides a component-defined, single-wavelength-activated platform for locally retained multimodal tumor therapy. Notably, this work represents the first report of a polypyridyl Ru(II)-scaffolded hydrogel that unifies Ru(II)'s structural coordination with intrinsic therapeutic action, offering a translational strategy for synergistic, site-selective tumor therapy.
- Open Access
- 14 February 2026
- Published by Taylor & Francis in Drug Delivery
- Vol. 33 (1) , 2630460
ROS-triggerable dual nanocoated probiotics for inflammatory bowel disease treatment
Inflammatory bowel disease (IBD), an immune-mediated chronic gastrointestinal disease, is difficult to treat because its specific pathogenic mechanisms are currently unclear, and its recurrence rate is high. Probiotic therapies have been used to treat IBD; however, challenges, including poor digestive stability and unstable treatment effects, remain. Catechins are natural flavonoids with anti-inflammatory and anti-oxidant properties. In this study, we link catechins to the amino side chain of ethylene glycol chitosan through phenylboronic acid as a nano coating for probiotics, and enhance their stability under acidic conditions with sodium alginate. The resulting double-layer nano coating system is triggered by reactive oxygen species (ROS) for probiotic-small molecule combination therapy. After oral administration, the nano coating helps probiotics stabilize and pass through the harsh digestive environment, respond to the high ROS environment at the site of inflammation, and release anti-inflammatory drugs. The coating breaks down and adheres to the cell surface while releasing probiotics to regulate the intestinal microbiota environment and achieve combined therapy. The method exerts a certain therapeutic effect in a dextran sulfate sodium (DSS)-induced mouse model of ulcerative colitis. This study combines traditional targeted drug therapy concepts with biological therapies to improve IBD treatment efficacy and reduce side effects.
- 14 February 2026
- Published by Taylor & Francis in Drug Delivery
- Vol. 33 (1) , 2630460
Open AccessROS-triggerable dual nanocoated probiotics for inflammatory bowel disease treatment
Inflammatory bowel disease (IBD), an immune-mediated chronic gastrointestinal disease, is difficult to treat because its specific pathogenic mechanisms are currently unclear, and its recurrence rate is high. Probiotic therapies have been used to treat IBD; however, challenges, including poor digestive stability and unstable treatment effects, remain. Catechins are natural flavonoids with anti-inflammatory and anti-oxidant properties. In this study, we link catechins to the amino side chain of ethylene glycol chitosan through phenylboronic acid as a nano coating for probiotics, and enhance their stability under acidic conditions with sodium alginate. The resulting double-layer nano coating system is triggered by reactive oxygen species (ROS) for probiotic-small molecule combination therapy. After oral administration, the nano coating helps probiotics stabilize and pass through the harsh digestive environment, respond to the high ROS environment at the site of inflammation, and release anti-inflammatory drugs. The coating breaks down and adheres to the cell surface while releasing probiotics to regulate the intestinal microbiota environment and achieve combined therapy. The method exerts a certain therapeutic effect in a dextran sulfate sodium (DSS)-induced mouse model of ulcerative colitis. This study combines traditional targeted drug therapy concepts with biological therapies to improve IBD treatment efficacy and reduce side effects.
- Open Access
- 19 July 2025
- Published by Elsevier in Materials Today Bio
- Vol. 34, 102107
Engineered lipid nanoparticles with synergistic dendritic cell targeting and enhanced endosomal escape for boosted mRNA cancer vaccines
- 19 July 2025
- Published by Elsevier in Materials Today Bio
- Vol. 34, 102107
Open AccessEngineered lipid nanoparticles with synergistic dendritic cell targeting and enhanced endosomal escape for boosted mRNA cancer vaccines